View Older Stories View More Recent Stories

May 11, 2017 07:00AM BioTime Presents Retinal Restoration Data at ARVO
May 10, 2017 04:01PM BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
May 9, 2017 07:50AM BioTime (BTX) Reports New Data from OpRegen Trial in Dry-AMD at ARVO Meeting
May 9, 2017 07:00AM BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
May 8, 2017 07:00AM BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
Apr 26, 2017 07:00AM BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Apr 24, 2017 07:00AM BioTime to Present Additional Data at Upcoming ARVO
Apr 6, 2017 07:00AM BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
Apr 4, 2017 07:00AM BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Mar 28, 2017 07:07AM BioTime (BTX) Announces Key Patents Upheld by European Patent Office
Mar 28, 2017 07:00AM Key BioTime Patents Upheld by European Patent Office
Mar 20, 2017 07:00AM BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
Mar 16, 2017 04:18PM BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Mar 15, 2017 07:00AM Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
Mar 13, 2017 07:00AM BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
Feb 23, 2017 07:17AM BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
Feb 21, 2017 06:48AM BioTime (BTX) Reports Deconsolidation of OncoCyte Inc.'s Financial Statements
Feb 21, 2017 06:45AM BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
Feb 15, 2017 04:01PM CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Feb 13, 2017 07:00AM BioTime to Present at Two Upcoming Investor Conferences
Feb 10, 2017 09:30AM Pre-Open Movers 02/10: (SHLD) (ICPT) (IMMU) Higher; (ONVO) (RSYS) (TCON) Lower (more...)
Feb 7, 2017 07:00AM BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Feb 6, 2017 07:05AM BioTime (BTX) Announces Acquisition of Global Rights to Ophthalmology-Related IP Assets From UPMC
Feb 6, 2017 07:00AM BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
Jan 26, 2017 08:00AM BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
Jan 19, 2017 07:00AM Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
Jan 3, 2017 07:00AM BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
Dec 14, 2016 07:00AM BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
Dec 12, 2016 07:00AM BioTime to Present at Global Bioproduction Summit
Dec 8, 2016 11:36AM BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit
Nov 18, 2016 05:55AM BioTime (BTX) Announces Presentation of Positive Data from Renevia Pivotal Trial
Nov 18, 2016 03:00AM Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
Nov 10, 2016 04:18PM BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016
Nov 3, 2016 04:01PM BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Nov 1, 2016 07:00AM Data From BioTime’s Renevia Pivotal Trial in HIV-Associated Facial Liopatrophy to be Presented at the 14th Annual IFATS Meeting on November 17
Oct 31, 2016 07:06AM BioTime (BTX) Names New SVP, Head of Corporate Development
Oct 31, 2016 07:00AM BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development
Oct 24, 2016 07:00AM BioTime, Inc. to Announce Third Quarter Results on November 3, 2016
Oct 20, 2016 06:32AM BioTime (BTX) Announces Presentation of OpRegen Phase 1/2a Data in Dry-AMD at ISOPT Symposium
Oct 20, 2016 06:30AM First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016
Oct 18, 2016 08:30AM Medidata Unveils AppConnect Partner Program
Oct 13, 2016 06:30AM BioTime to Present at the BIO Investor Forum
Sep 23, 2016 07:00AM BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 15, 2016 04:08PM BioTime (BTX) Affirms Announcement of Positive AST-OPC1 SCiSTAR Phase 1/2a Data (AST)
Sep 15, 2016 04:07PM BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
Sep 6, 2016 08:00AM BioTime to Present at Two Upcoming Investor Conferences
Aug 15, 2016 08:00AM BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine
Aug 9, 2016 04:18PM BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
Jul 27, 2016 08:45AM BioTime, Inc. to Report Second Quarter Results on August 9, 2016
Jul 5, 2016 11:35AM BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
View More Recent Stories View Older Stories